Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.

Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.

The present invention provides a method of manufacture of a liposome composition including a step in which: a liposome dispersion liquid containing a liposome, and further containing cyclodextrin in the liposome internal phase is provided and a step in which an active compound is introduced into said liposome internal phase, and the liposome composition.

The invention relates to self-assembled architectures formed from polymer-lipid blends, and in particular, to tubular and vesicular self-assembled architectures formed from polymer-lipid blends. The invention further relates to a method for forming the tubular and vesicular self-assembled architectures. The invention provides a composition comprising a lipid and an amphiphilic block copolymer, wherein the amphiphilic block copolymer is capable of undergoing self-assembly to form an architecture of a first geometry, wherein the composition undergoes self-assembly to form a bilayer architecture enclosing a volume of a second geometry, wherein the second geometry is different from that of the first geometry.

A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.

The present invention relates to liposomes that encapsulate uric acid, methods for its preparation and uses of said liposomes.

Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

Provided herein is a method of producing a protein comprising a target-specific extravesicular domain (TED) of an extracellular vesicle (EV) surface protein comprising modifying a polynucleotide comprising a nucleotide sequence encoding the extravesicular domain (ED) of an EV surface protein by a mutagenesis method within at least one modified region within the ED amino acid sequence with a length of 3-20 contiguous amino acids flanked by regions of the wild-type ED sequence at its N-terminus and C-terminus, to incorporate a target binding site within the ED, thereby producing a repertoire of polynucleotides encoding a variety of TEDs, each comprising a different target binding site, and selecting a TED specifically recognizing a predetermined target, and producing the protein comprising the selected TED.

The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a suspension of preformed lipid nanoparticles and mRNA.

Provided herein is technology relating to incorporation of drugs into liposomes and particularly, but not exclusively, to methods for incorporating drugs into liposomes using a weak base and related compositions.